Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 216-613-3 | CAS number: 1624-62-0
Endpoint summary
Administrative data
Description of key information
Acute toxicity oral: LD50 > 2000 mg/kg bw (Kurth 1994)
Acute toxicity dermal: LD50 > 2000 mg/kg bw (Kurth 1996)
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 29. Sep to 02. Nov 1994
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- study was conducted prior to implementation of OECD TG 423
- Deviations:
- yes
- Remarks:
- The application of 2000 mg/kg to three animals was repeated with three animals of a different sex.
- GLP compliance:
- yes
- Test type:
- acute toxic class method
- Limit test:
- yes
- Specific details on test material used for the study:
- - Solubility and stability of the test substance in the solvent/vehicle: The mycrorystalline suspensions were prepared fresh on application day for immediate application and administrations were carried out within approximately 2 hours after preparation. The stability of the test item was verified analytically. In addition all samples are considered prepared correctly with regard to the results of analysis.
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Schering AG
- Weight at study initiation: males: 94-104 g; females: 91-97 g
- Fasting period before study: ca. 18-18.5 hours
- Housing: 1/cage
- Diet (e.g. ad libitum): pell. Altromin R, ad libitum
- Water (e.g. ad libitum): demineralized acidified water, pH 2-3, ad libitum
- Acclimation period: 7 d
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21-23°C
- Humidity (%): 48-58%
- Photoperiod (hrs dark / hrs light): 12/12
- Route of administration:
- oral: gavage
- Vehicle:
- other: Miglyol 812
- Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- 3/sex
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of weighing: day 8 and 14
- Necropsy of survivors performed: yes - Statistics:
- Not applicable.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- no mortality
- Clinical signs:
- other: Transient clinical signs (apathy and atactic gait). All animals were without treatment-related findings from day 2 onwards.
- Gross pathology:
- no effects observed
- Conclusions:
- The single oral administration of the test item to male and female Wistar rats at the dose of 2000 mg/kg resulted in transient clinical signs (apathy and atactic gait). All animals were without treatment-related findings from Day 2 onwards. No compound-related macroscopic findings were seen. The acute oral toxicity of the test item in rats is above 2000 mg/kg body weight.
- Executive summary:
In an acute oral toxicity study similar to OECD TG 423, fasted Wistar rats (3/sex) were given a single oral dose by gavage of estrone-methylether in Miglyol 812 at the limit dose 2000 mg/kg and observed for 14 days.
The administration of the test item resulted in transient clinical signs (apathy and atactic gait). All animals were without treatment-related findings from Day 2 onwards. No compound-related macroscopic findings were seen. The acute oral toxicity of estrone-methylether in rats is above 2000 mg/kg body weight.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 13. July to 14. Aug 1995
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Version / remarks:
- 1981
- Deviations:
- yes
- Remarks:
- 3 instead of 5 animals/sex used
- GLP compliance:
- yes
- Test type:
- fixed dose procedure
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Schering AG
- Weight at study initiation: males: 109-115 g; females: 96-107 g
- Fasting period before study: ca. 19 hours
- Housing: 1/cage
- Diet (e.g. ad libitum): pell. Altromin R, ad libitum
- Water (e.g. ad libitum): demineralized acidified water, pH 2-3, ad libitum
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 23-24°C
- Humidity (%): 42-60%
- Photoperiod (hrs dark / hrs light): 12/12
- Type of coverage:
- not specified
- Vehicle:
- physiological saline
- Remarks:
- 900 mg NaCI + 85 mg Myrj® 53 ad 100 ml bidist. water
- Duration of exposure:
- 24 hours
- Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- 3/sex
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: start (day 1), on day 7 and at the end (day 14) of the study
- Necropsy of survivors performed: yes
- Other examinations performed: evaluation of local tolerance 24, 48 and 72 hours after the end of administration - Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- no mortality occurred
- Clinical signs:
- other: The test substance was tolerated without any clinical findings.
- Gross pathology:
- The test substance was tolerated without any macroscopic pathological findings.
- Conclusions:
- The single dermal, 24 h-administration of estrone methylether to male and female Wistar rats at the dose of 2000 mg/kg was tolerated without any clinical or macroscopic pathological findings. The acute dermal toxicity of the test item is above 2000 mg/kg body weight.
- Executive summary:
In an acute dermal toxicity study similar to OECD TG 402 performed as a combined study on acute toxicity and on local tolerance Wistar rats (3/sex) (3/sex) were dermally exposed to estrone methylether in physiological saline for 24 hours at a limit dose of 2000 mg/kg bw. Animals then were observed for 14 days.
The administration of the test substance was tolerated without any clinical or macroscopic pathological finding. The dermal LD50 of the test substance is therefore > 2000 mg/kg body weight.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
Additional information
In an acute oral toxicity study similar to OECD TG 423, fasted Wistar rats (3/sex) were given a single oral dose by gavage of estrone-methylether in Miglyol 812 at the limit dose 2000 mg/kg and observed for 14 days.
The administration of the test item resulted in transient clinical signs (apathy and atactic gait). All animals were without treatment-related findings from Day 2 onwards. No compound-related macroscopic findings were seen. The acute oral toxicity of estrone-methylether in rats is above 2000 mg/kg body weight (Kurth, 1994).
In an acute dermal toxicity study similar to OECD TG 402 performed as a combined study on acute toxicity and on local tolerance Wistar rats (3/sex) (3/sex) were dermally exposed to estrone methylether in physiological saline for 24 hours at a limit dose of 2000 mg/kg bw. Animals then were observed for 14 days.
The administration of the test substance was tolerated without any clinical or macroscopic pathological finding. The dermal LD50 of the test substance is therefore > 2000 mg/kg body weight (Kurth, 1996).
Comparable to these results RTECS states a LD50 > 5000 mg/kg for acute oral toxicity in rats and mice for estrone (used as a source for read-across in other endpoints) and thereby supports the conclusion of no acute toxicity potential for these structural analogues. No inhouse studies with estrone on the endpoint acute toxicity were conducted.
In conclusion, estrone-3-methylether is not classified (Reg. (EC) No. 1272/2008) for both acute oral and acute dermal toxicity.
Acute toxicity studies for estrone-3-methylether
| Estrone-3-methylether (CAS 1624-62-0) | |
Study type | Acute oral | Comb. acute dermal & local tolerance |
Study no./ Report no. | TX94.250 (draft version) Kurth, 1994 | TX95190/ X052 (draft version) Kurth, 1996 |
GLP/ OECD TG/ deviations | GLP, equivalent to OECD 423 (limit study) Dev.: 2 sexes instead of 1; no individual animal reporting but means per sex with low & acceptable standard deviations scope of report limited related to actual TG 423 (acute toxic class method, adopted version Dec 2001) but sufficient for assessment | GLP, comparable to OECD 402 (limit study) & 404 Dev.: 2 sexes instead of 1, with n=3 animals per sex; no individual animal reporting but means per sex with low & acceptable standard deviations; scope of report limited related to actual TG 402 (2017) and TG 404 (July 2015), but sufficient for assessment |
Species; animals/ group | Rat (Wistar), n=3 female/ male | Rat (Wistar), n=3 female/ male |
Doses/ route/ schedule | 2000 mg/kg (200 mg/ml) p.o., single treatment | 2000 mg/kg, dermal (semi-occlusive), 24h-exposure, single treatment |
Formulation | · Batch no. 11427106; purity 96.1% (according to certificate of analysis no. 944647, dated 27 Jul. 94); information on stability in formulation not given · Microcristalline suspension in Miglyol 812; freshly prepared and administrated within 2h · Compound concentrations of 98-93% (applied to male rats) and 95% (applied to female rats) confirmed by HPLC with UV detection (analytical report SFR-KI 94113) | · Batch no. 11427106; purity 96.1% (according to certificate of analysis no. 944647, dated 27 Jul. 94); information on stability in formulation not given · Suspension in 900 mg NaCI + 85 mg Myrj® 53 ad 100 ml bidist. water; freshly prepared · Compound concentrations of 112% (applied to male rats) and 101% (applied to female rats) determined by HPLC with UV detection (analytical report SFR-KI 95118) |
observation period | 14d | 14 d, (for scoringof skin irritation parameters 24h, 48h 72h) |
Results | · Clinical signs: apathy and atactic gait after application; no findings from day 2 onwards · Increasing BW (mean values per sex) over time · No animal died · No findings within gross necropsy · LD50 > 2000 mg/kg | · No local findings on skin at the application sites (no reddening, scab formation or swelling of the skin) · Compound tolerated without any clinical signs · Increasing BW (mean values per sex) over time · No animal died · No findings within gross necropsy · LD50 > 2000 mg/kg |
Reliability | 2 | 2 |
Justification for classification or non-classification
Based on the available data no classification for acute toxicity (oral, dermal) according to Regulation (EC) No. 1272/2008 (CLP) is required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
